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ABSTRACT
Background: Poly-(ADP-ribose)-polymerase1 (PARP1) is involved in repair of 
DNA single strand breaks. PARP1-inhibitors (PARP1-i) cause an accumulation of DNA 
double strand breaks, which are generally repaired by homologous recombination 
(HR). Therefore, cancer cells harboring HR deficiencies are exceptionally sensitive to 
PARP1-i. For patients with HR-proficient tumors, HR can be temporarily inhibited by 
hyperthermia, thereby inducing synthetic lethal conditions in every tumor type. Since 
cisplatin is successfully used combined with hyperthermia (thermochemotherapy), 
we investigated the effectiveness of combining PARP1-i with thermochemotherapy. 
Results: The in vitro data demonstrate a decreased in cell survival after addition 
of PARP1-i to thermochemotherapy, which can be explained by increased DNA damage 
induction and less DSB repair. These in vitro findings are in line with in vivo model, in 
which a decreased tumor growth is observed upon addition of PARP1-i.
Materials and Methods: Survival of three HR-proficient cell lines after cisplatin, 
hyperthermia and/or PARP1-i was studied. Cell cycle analyses, quantification of 
γ-H2AX foci and apoptotic assays were performed to understand these survival data. 
The effects of treatments were further evaluated by monitoring tumor responses in 
an in vivo rat model. 
Conclusions: Our results in HR-proficient cell lines suggest that PARP1-i combined 
with thermochemotherapy can be a promising clinical approach for all tumors 
independent of HR status.
INTRODUCTION
Many cancer treatment modalities either interfere 
with DNA metabolism or with the repair of DNA damage. 
Combination of different, carefully selected modalities 
can enhance clinical outcomes. Here, we investigate the 
effectiveness of different combinations of three modalities 
which interfere with DNA integrity or DNA repair: cisplatin 
(cDDP), mild hyperthermia (heating the tumour to 40–43°C 
for 1 h) and Poly-(ADP-ribose)-polymerase1 inhibitors 
(PARP1-i).
A high percentage of breast and ovarian cancers 
(~50–85% and ~30–66 %, respectively) are caused by 
mutations in BRCA1 or BRCA2 genes [1–4]. Tumours with 
mutations in either of these genes require homologous 
recombination (HR) for repair [5]. Inactive HR can be 
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due to mutations in BRCA1 or BRCA2, which may result 
in potentially lethal accumulation of DNA double strand 
breaks (DSBs). HR-deficient (c.q. BRCA-deficient) cells 
are thus exquisitely sensitive to PARP1-i [6]. Importantly, 
this also implies that healthy, HR-proficient cells are 
not targeted by PARP1-i, which makes this therapy 
particularly desirable for patients with HR-deficient 
tumours [5, 7]. Clinical trials have indeed confirmed the 
effectiveness of PARP1-i as a single treatment against 
BRCA-deficient tumours [8, 9]. 
In HR-proficient tumours, synthetic lethality can 
also be induced by combining PARP1-i with a local 
treatment of mild hyperthermia [5, 6, 10–15], which 
causes degradation of BRCA2 for several hours [13] 
and thereby HR deficiency at the heated tumour site. 
Combination of hyperthermia (HT) with PARP1-i thus 
creates a possibility to induce synthetic lethality in every 
tumour type that can be heated locally [13, 16]. Cisplatin 
(cDDP) is a widely used chemotherapeutic agent that is 
combined with HT (hence called thermochemotherapy) as 
standard treatment for previously irradiated patients with 
recurrent cervical a . behind  [17–19] cDDP induces DSBs 
that are usually repaired by HR, because cDDP disrupts 
the non-homologous end joining (NHEJ), the other major 
DSB repair pathway [20, 21]. In absence of HR and NHEJ, 
a PARP1-dependent back-up NHEJ (b-NHEJ) pathway can 
take over the repair of DSBs [22]. As a consequence, a 
combination of HT, cDDP and PARP1-i could potentially 
cause an overload of DSBs while simultaneously 
interfering with all major DSB repair pathways [23]. The 
accumulation of unrepaired DSBs can result in cell death. 
In this study, HR-proficient cell lines (R1, SiHa, 
HeLa) and a HR-proficient rhabdomyosarcoma allograft 
model were used to investigate the effectiveness of 
treatments combining PARP1-i, with mild HT and cDDP. 
Cell survival as well as cell cycle analyses, quantification 
of γ-H2AX foci and apoptotic assays were performed. 
Finally, the effects of the different treatments on tumour 
outgrowth were measured in vivo.
RESULTS 
Addition of PARP1-i to cDDP-based 
thermochemotherapy diminishes cell survival
The response of cells to HT was investigated for 
BRCA2 levels (Figure 1A). After HT, BRCA2 levels are 
downregulated. Effects of HT on homologous recombination 
were studied by scoring co-localization of Rad51 and 
γ-H2AX (Figure 1B). After RT alone, a clear co-localization 
of γ-H2AX, a protein detecting DNA double strand breaks 
and Rad51, a protein involved in homologous recombination 
is observed. After RT + HT, Rad51 foci are absent, 
indicating homologous recombination is not active anymore. 
To directly evaluate the effect of combinations of treatments 
with HT, cDDP and PARP1-i, clonogenic assays were 
conducted using the R1, SiHa and HeLa cells (Figure 1C). 
For all cell lines, therapy with the PARP1-i alone killed 
30–40% of the cells. As such, treatment with PARP1-i was 
only slightly more effective than HT as a single treatment. 
cDDP was the most effective monotherapy. The combination 
treatment of PARP1-i with HT was equally effective as 
cDDP alone, and more effective than PARP1-i or HT alone. 
PARP1-i combined with cDDP was more effective than 
cDDP alone in the R1 cell line. In SiHa and HeLa cells, 
PARP1-i plus cDDP demonstrated a small decrease in cell 
survival, compared to cDDP alone. Combinational treatment 
of cDDP and HT was highly toxic and around 80–90% of 
the cells did not survive this treatment. 
The addition of PARP1-i to cDDP-based 
thermochemotherapy caused a higher than 2-fold reduction 
in cell survival in R1 cells, an almost 2-fold reduction in 
SiHa cells and a ~1.5-fold reduction in HeLa cells.
Triple modality treatment leads to accumulation 
of DNA damage
Formation of γ-H2AX, which represents unrepaired 
DSBs, was analysed by flow cytometry, in order to identify 
a possible mechanism for differences in cell survival 
analyses after the triple modality treatment (Figure 2A). 
Cells grown on cover slips, treated with different 
combinations of cDDP, HT and PARP1-i were used 
for immunocytochemistry. For each condition one 
representative cell is depicted in Figure 2B. An up to 
1.5-fold increase in γ-H2AX intensity was found after 
any of the single- and double-treatments. The load of 
DNA damage after addition of PARP1-i to cDDP-based 
thermochemotherapy was significantly higher than after 
cDDP-based thermochemotherapy alone.
Triple modality treatment increases the fraction 
of cells in S-phase 
Cell cycle distribution was studied by incorporation 
of BrdU. In the untreated samples, ~50% of R1, SiHa and 
HeLa cells were in G1-phase, ~40% in S-phase and ~10% 
in G2-phase of the cell cycle (Figure 3). Treatment with 
PARP1-i caused modest changes in cell cycle distribution, 
while after HT a slight decrease in G1 cells was observed, 
combined with a minor increase of cells in the G2-phase. 
Of all monotherapies, cDDP had the strongest effects 
on cell cycle distribution in R1 cells, causing increased 
fraction of S-phase cells, as compared to the control. 
Moreover, in all cell lines, an increased proportion of cells 
in S-phase was found after a single treatment with cDDP 
and hyperthermia and after the triple modality.
Addition of PARP1-i to cDDP and hyperthermia 
increases apoptosis
To examine whether cell death detected in the 
clonogenic assays is due to induction of apoptosis, a 
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Nicoletti assay was performed. The results of this assay 
demonstrate a 2 to 5-fold induction in apoptotic levels in 
R1 cells after any combination of treatment, except after 
the triple modality, for which there was an almost 9-fold 
induction of apoptosis (Figure 4). The degree of induction 
differed per cell line, but the trend was similar for all 
tested cell lines.
The triple modality treatment delays tumour 
outgrowth in vivo
In vivo, tumours were treated with any combination 
of PARP1-i, HT and cDDP to test whether the therapy 
induces similar effects in vivo as in vitro. In untreated rats 
the tumour volume increased approximately exponentially, 
without a significant change in the slope of the growth 
curve. A treatment with cDDP alone, cDDP combined 
with either PARP1-i or HT, or cDDP combined with both 
induced a change in the steepness of the curve (Figure 5A), 
indicating that these treatments contributed to tumour 
control. Effects on tumour growth delay range from modest 
in the groups treated with PARP1-i, HT and HT+PARP1-i 
to substantial after cDDP alone, PARP1-i + cDDP, PARP1-i 
combined with HT and the triple modality. The differences 
in tumour growth were also calculated as the period of 
time needed to reach 10 times the tumour starting volume 
(T10 × SV) (Figure 5B). While the mono-therapies had 
only marginal influence on reaching T10 × SV, compared 
to the untreated animals, the double treatments did cause 
a delay of a few days. The highest level of tumour control 
was seen after the triple modality treatment, where the 
tumours took, on average, almost twice as long to reach 
the T10 × SV, as compared to the single therapies and 
approximately 1.5 times longer compared to cDDP-based 
thermochemotherapy. Importantly, no (acute) toxicities 
were detected in any of the rats.
DISCUSSION AND CONCLUSIONS
Our data demonstrated that addition of PARP1-i 
to cDDP-based thermochemotherapy results in an 
almost 2-fold reduction in cell survival, as compared to 
cDDP-based thermochemotherapy alone. This can be 
explained in part by an increased induction of apoptosis, 
which might be due to the higher DNA damage load, as 
indicated by γ-H2AX analysis. This, in turn, could result 
in increased activation of the S/G2 checkpoint, as we 
observed a higher fraction of cells in S-phase after cDDP-
based thermochemotherapy and an even more profound 
increase after the triple modality treatment. Prolonged 
Figure 1: The effects of PARP1-i, HT, cDDP and combined treatments on BRCA2, Rad51 and cell survival are shown. 
(A) Western blots demonstrating R1, SiHa and HeLa cells are BRCA2 proficient. After HT, BRCA2 is downregulated. (B) γ-H2AX and 
Rad51 co-localization, to investigate activity of homologous recombination. (C) Clonogenic assays were performed to study the effect of 
the different treatment combinations, 10–12 days after treatments. The addition of PARP1-i to cDDP-based thermochemotherapy resulted 
in a significantly lower cell survival compared to cDDP-based thermochemotherapy alone. R1: p = 0.0008, SiHa: p = 0.034, HeLa: 
p = 0.021. The bar graph shows the mean of at least five independent experiments. From left to right: R1, SiHa, Hela cells. *p < 0.05, 
**p < 0.01, ***p < 0.001.
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Figure 2: DSBs were analysed using the γ-H2AX assay. (A) The induction of DSBs in R1 and SiHa was significantly higher after 
addition of PARP1-i to cDDP-based thermochermotherapy. In HeLa cells this was not found to be significant, although a trend is seen. 
R1: p = 0.048, SiHa: p = 0.035, HeLa: p = 0.068 From left to right: R1, SiHa, Hela cells. (B) One representative cell is depicted for each 
condition. Bars represent the mean of three independent experiments with the standard error of the mean (SEM). *p < 0.05.
Figure 3: Cell cycle distribution using BrdU incorporation. While the monotherapies hardly ever changed the cell cycle 
analyses, any treatment containing cDDP resulted in a larger proportion of cells in S-phase. The differences found after adding PARP1-i to 
thermochemotherapy were not significant. From left to right: R1, SiHa, Hela cells. 
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cell cycle block could eventually lead to apoptosis. It is 
important to stress that all these effects were caused by 
a single treatment session and we expect that a repeated 
treatment regimen, more akin to clinical settings, would 
lead to stronger responses.
After the last treatment the tumour growth 
recovered. Although the double treatment with 
HT+cDDP and PARP1-i+cDDP were almost as effective 
in controlling tumour growth (Figure 5A), in terms of 
reaching ten times the start volume, the triple modality 
considerably delays tumour growth.
Clinical trials that have been performed on patient 
with BRCA-deficient tumours received daily Olaparib, 
sometimes even twice a day [8]. However, in our study, we 
mimic the BRCA-deficiency by applying HT. This results 
in a temporary downregulation of BRCA and within 
this timeframe, the PARP1-i should be administered. 
Therefore, the animals in our study were treated twice a 
week with two times Olaparib and one dose of cisplatin 
on the day of HT treatment. Thus, although it is not an 
identical schedule to the previous clinical trials with 
Olaparib, it is the most optimal scheme for treating 
BRCA-proficient tumours with HT and PARP1-i. As a 
consequence, since we have not treated daily, and only for 
a period of three weeks, it may be a valid consideration 
to extend the treatments with a couple of weeks, as HT 
sessions in patients are normally given once or twice a 
week for a period of five weeks in our center. Therefore, 
the outcomes of this study are promising, because we 
have treated these tumours with just 60% of the normal 
Figure 4: Apoptotic levels measured using the Nicoletti assay. An ~1.5-fold induction in apoptosis is found after treatment 
with PARP1-i, cDDP and HT compare to cDDP with HT in R1 and SiHa cells (R1: p = 0.0007, SiHa: p = 0.0054). A smaller, though 
significant effect was found in HeLa cells after addition of a PARP1-i (HeLa: p = 0.026).  From left to right: R1, SiHa, Hela cells. *p < 0.05, 
**p < 0.01, ***p < 0.001. 
Figure 5: In vivo experiments performed on rats. (A) Relative tumour volume demonstrated that PARP1-i enhanced the effectiveness 
of cDDP-based thermochemotherapy and reduced the in vivo tumour outgrowth. Arrows present the time of treatment. (B) Time needed to 
achieve ten times the start volume (T10 × SV). Animals treated with the triple modality showed a delay in reaching T10 × SV compared to 
thermochemotherapy or any single treatment. All animal experiments included at least five rats per group. 
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HT scheme and already the tumour shrank to its starting 
volume. However, an additional agent to standard 
thermochemotherapy may increase toxicity levels. 
Whether this occurs should be investigated.
There is growing evidence that platinum-based 
agents can also contribute in interfering with HR, resulting 
in HR-deficiency [24]. Subsequently, it might be interesting 
to combine platinum-based agents with PARP1-i. However, 
some people state that the use of PARP1-i may be limited 
in the clinic due to an increase in observed toxicities in 
combination with chemotherapeutic agents [25, 26]. 
The triple modality that we propose, PARP1-i combined 
with cDDP-based thermochemotherapy might have more 
potential, because HT can make chemotherapeutic agents 
penetrate more deeply into the tumour and HT targets 
hypoxic areas, which are generally least sensitive to other 
anti-cancer therapies. Thus, lower chemotherapeutic dose 
may be as effective as normal concentrations without HT, 
but at a reduced toxicity [16]. 
In summary, there have been many studies that use 
the HR-deficiency in BRCA-mutated tumours to induce 
potentially lethal DNA damages by inhibition of PARP1. 
The advantage of our study is the possibility to treat BRCA-
proficient cells with an already successful clinically applied 
therapy that can temporarily inhibit the HR. Therefore, we 
may induce synthetic lethality for any tumour type.
MATERIALS AND METHODS
Cell lines and cell culture
Rat rhabdomyosarcoma cells (R1, a cell line 
developed in our own institute for in vitro cultures as 
well as for in vivo growing tumors [27]) were grown in 
MEM. The cervical carcinoma cells (SiHa and HeLa) 
were obtained from the American Type Culture Collection 
(ATCC) and grown in EMEM. All cell lines are BRCAwt. 
All media contained 25 mM Hepes (Gibco-BRL life 
technologies, Breda, The Netherlands) supplemented 
with 10% heat-inactivated foetal bovine serum (FBS) 
and 2 mM glutamine. Cells were maintained in a 37°C 
incubator with humidified air supplemented with 2% and 
5% CO2, respectively. The cell division time of R1 cells 
was approximately 16 h and of SiHa and HeLa cells 24 h.
In vitro treatments
Cells were treated for approximately 60 min with 
5 µM cisplatin (cDDP; Platosin®, Pharmachemie B.V., 
Haarlem, The Netherlands) and/or continuously with 
100 µM of PARP1-i (dissolved in DMSO; NU1025, Tocris 
Bioscience, Bristol, UK). cDDP was added 5 minutes 
before HT, while PARP1-i was added 30 min prior to the 
HT treatment. Immediately after HT, medium was refreshed 
and PARP1-i was re-added until the end of the experiment. 
HT was performed by partially submerging the 
culture dishes in a thermostatically controlled water 
bath (Lauda aqualine AL12, Beun de Ronde, Abcoude, 
The Netherlands) for 1 h at 42°C. In order to check the 
temperature, thermocouples were placed in parallel culture 
dishes; the desired temperature (± 0.1°C) was reached in 
approximately 5 min. HT was performed in an atmosphere 
containing 2% (R1 cells) or 5% (SiHa and HeLa cells) 
CO2 with gas mixture inflow rate of 2 L/min. 
Western blotting 
To identify the BRCA2 status of these cell lines, 
western blots were conducted. Also, the response to HT was 
tested. Cells were harvested 30 min post treatment. Next, 
pellets were lysed on ice in ice-cold RIPA buffer (20 mM 
Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 1% NP-40, 
1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 
1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 μg/ml 
leupeptin) with protein inhibitors for 30 min [28]. 
Laemmli buffer containing fresh added 2-mercaptoethanol 
(355 mM) was mixtued to the supernatant (1:1), before 
heated in boiling water for 2–5 min. Finally, samples 
were sonificated (Sonics & Materials Inc). One μg of 
protein was loaded on 4–15% SDS-PAGE gradient precast 
gels (BioRad) and transferred to PVDF membranes. 
Loading of protein were checked by Ponceau S staining. 
Immunodetection was performed for anti-BRCA2 
(antibodies-online) and anti-ERK2 (Bethyl Laboratories), 
and a secondary anti-rabbit (Invitrogen Life Technologies). 
All samples were enhanced using chemoluminescence 
(Amersham Pharmacia Biotech). Eventually, blots were 
analysed using LAS4000 (GE, Healthcare life sciences).
Co-localization of Rad51 and γ-H2AX foci 
Activity of homologous recombination has been 
investigated by co-localization of Rad51 and γ-H2AX 
foci. Cells were plated on 1.8 μm mylar membrane dishes. 
One day later, cells were treated with or without HT prior 
to a min irradiation of α-particles. Afterwards, 30 min after 
treatment, cells were fixed with 2% paraformaldehyde. 
Cells were washed with PBS and permeabilized during a 
30-minute incubation with TNBS (PBS containing 0.1% 
Triton X-100 and 1% FCS), before staining with γ-H2AX 
(Millipore, dilution 1:100 in TNBS) and Rad51 antibody 
(dilution 1:25 in TNBS) as described by Bergs et al [29]. 
Eventually, a drop of vectashield containing DAPI (Life 
technologies, USA) was pipetted in the slide and the 
coverslip is turned upside down on the slide. Samples 
were scored under the fluorescence microscope. 
Cell survival assay 
Cell survival was studied for R1, SiHa and HeLa cells 
using different combinations of HT, cDDP and PARP1-i. 
Clonogenic assays were conducted as described by Franken 
et al. [30]. Cells were plated at 4 h prior to treatment into 
6-well culture plates (Costar, USA). Dishes were placed 
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in a 37°C incubator with the desired percentages of CO2 
at 37°C until sufficiently large clones were formed, which 
took approximately 10–12 days. Afterwards, the medium 
was removed and cells were washed with PBS before a 
30-min incubation in a 2–3 ml of a mixture containing 
6.0% glutaraldehyde and 0.5% crystal violet, at room 
temperature. Finally, plates were washed with tap water and 
dried at room temperature. Colonies were counted under a 
light microscope [31]. Surviving fractions were calculated 
by dividing the plating efficiency of treated cells by that of 
control cells [32].
Detection of DNA DSBs quantifying γ-H2AX foci 
and flow cytometric detection of γ-H2AX 
To identify a possible mechanism for the 
differences in cell survival after the triple modality 
treatment, we quantified the formation of γ-H2AX, 
representing unrepaired DSBs, by flow cytometry. For 
immunocytochemistry, to present a representative image, 
cells were plated 24 h before any combination of cDDP, 
PARP1-i and HT treatment on sterile coverslips. On the 
next day, cells were fixed for 10 min in PBS containing 
2% paraformaldehyde, three times washed with PBS. 
Then, cells were permeabilised during a 30-min incubation 
in TNBS (PBS containing 0.1% Triton X-100 and 1% 
FCS). Afterwards, cells were stained for 90 min at room 
temperature with 50 μl primary antibody of a mouse 
monoclonal anti-γ-H2AX (Millipore, dilution 1:100 in 
TNBS). Cells were washed once in PBS and two times 
in TNBS before staining for 30 min at room temperature 
with a secondary antibody anti-mouse Cy3 (Jackson, 
diluted 1:100 in TNBS). After three times washing with 
TNBS, vectashield-containing DAPI (Life technologies, 
USA) was dropped onto glass slides, before placing the 
coverslips upside-down on the slides. γ-H2AX foci were 
scored under a fluorescence microscope.
To quantify γ-H2AX using flow cytometry, the 
staining was performed at 24 h after treatment. Cells were 
centrifuged (1200 rpm, 10 min), prior to fixation in a 
mixture containing 2 ml PBS and 6 ml absolute ethanol. 
Next day, cells were washed and incubated on ice for 10 min 
with PBS + 0.1% triton and 4% BSA. After centrifugation, 
cells were stained with antibodies against γ-H2AX-FITC 
(4 µg/ml, Merck Millipore, USA). Samples were then 
analysed using FACS Canto (BD Biosciences, USA).
Cell cycle analysis
The thymidine analogue 5-Bromo-2′-deoxy-uridine 
(BrdU, Sigma Aldrich, USA) was used to analyse cell 
cycle distribution. At 16 h after treatments, BrdU (diluted 
1:100) was added for 60 min at 37°C, before fixating cells 
in a mixture containing 2 ml PBS and 6 ml of absolute 
ethanol. Cells were stored at 4°C.  The next day, after 
spinning down samples at 1200 rpm for 2 min, pellets 
were resuspended in pepsin-HCl (0.4 mg/ml, 0.1 N HCl) 
and cells were incubated for 30 min at room temperature. 
Cells were then washed with PBT (PBS containing 0.5% 
Tween-20 (Sigma Aldrich USA)). After centrifugation, 
pellets were resuspended in HCl (2 N, Merck) and 
incubated for 30 min at 37°C. Next, cells were stained 
with rat-anti-BrdU primary antibody (Abcam, UK) diluted 
1:100 in PBTb (1% bovine serum albumin, Sigma, in PBT) 
for 60 min at 37°C. After washing cells two times with 
PBT and once with PBTg (PBT containing 1% normal 
goat serum (Dako, USA), cells were stained with a goat-
anti-rat secondary antibody labelled with FITC (Abcam, 
UK) diluted 1:100 in PBTg for 60 min at 37°C. Cells were 
washed three times with PBS before resuspending the 
pellets in PBS. Finally, propidium iodide (Sigma-Aldrich, 
USA) was added and cell suspensions were vortexed. 
Analysis was performed using the FACS Canto flow 
cytometer (BD Biosciences, USA). 
Apoptosis assay
To study apoptosis after any combination of 
treatments, the Nicoletti assay [30] was performed. Cells 
were collected 48 h after the different treatments and 
pellets were resuspended in Nicoletti buffer (0.1% w/v 
Sodium citrate, 0.1% v/v Triton X-100 in demi water, 
pH  7.4), containing propidium iodide (Sigma-Aldrich, 
USA). Analyses were performed using the FACS Canto 
flow cytometer (BD Biosciences, USA). 
Animal experiments
Female WAG-Rij rats were implanted with 1 mm3 
piece of rhabdomyosarcoma tumour tissue in the right hind 
leg. After approximately three weeks, when the tumours 
had grown to 50–100 mm3, the animals were treated twice 
a week for a period of 3 weeks. The treatment involved 
HT for 1.5 h at 42°C in a thermostatically controlled water 
bath. In order to monitor the temperature thermocouples 
were placed next to the tumours. Earlier experiments 
[13, 34] demonstrated that when the water bath was 
set to 42.7°C, the intra-tumour temperature was 42°C. 
Animals were cooled to prevent them from receiving 
whole body hyperthermia. The PARP1 inhibitor Olaparib 
was dissolved in a mixture of 10% 2-hydroxy-propyl-β-
cyclodextrin and 10% DMSO in PBS and administrated 
at a dosage of 50 mg/kg p.o. 16 h and 2 h prior to HT. 
cDDP (Platosin®, Pharmachemie B.V., Haarlem, The 
Netherlands) was given i.p. at the dosage of 2.0 mg/kg 
2 h prior to hyperthermia. Animal weight was monitored 
every two days and tumour sizes were measured using 
a Vernier caliper every two days, until the end of the 
experiment. Animals were sacrificed when the tumour 
volume exceeded 3500 mm³. The treated hind leg of rats 
was checked every two days for skin irritation. All animal 
experiments included at least five rats per group.
Oncotarget28123www.impactjournals.com/oncotarget
Statistical analyses
All in vitro data represent means (of at least three 
experiments) with standard error of the mean (SEM) of 
at least three independent experiments. SPSS (Chicago, 
IL, USA) statistical software using a non-parametric 
Mann-Whitney test was used to analyse cell survival, 
γ-H2AX foci and apoptosis. P-values lower than 0.05 
were considered statistically significant.
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